Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types.
Razvan CristescuMichael NebozhynChunsheng ZhangAndrew AlbrightJulie KobieLingkang HuangQing ZhaoAnran WangHua MaZ Alexander CaoMichael MorrisseyAntoni RibasPetros D GrivasDavid W CesconTerrill K McClanahanAlexandra SnyderMark AyersJared LuncefordAndrey LobodaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
These findings suggest that features beyond IFNγ-related T-cell inflammation may be relevant to anti-programmed death 1 monotherapy response and may define other axes of tumor biology as candidates for pembrolizumab combinations. See related commentary by Cho et al., p. 1479.